The U.S. Food and Drug Administration granted Breakthrough Therapy designation to Austin, Texas-based Savara Inc.’s Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP).
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-01-02 12:20:032020-01-02 12:20:03Savara’s Roller-Coaster Ride Continues As Molgradex Earns Breakthrough Therapy Designation from FDA